keyword
MENU ▼
Read by QxMD icon Read
search

treatment of schizophrenia

keyword
https://www.readbyqxmd.com/read/29334044/gene-environment-interplay-in-the-etiology-of-psychosis
#1
Alyson Zwicker, Eileen M Denovan-Wright, Rudolf Uher
Schizophrenia and other types of psychosis incur suffering, high health care costs and loss of human potential, due to the combination of early onset and poor response to treatment. Our ability to prevent or cure psychosis depends on knowledge of causal mechanisms. Molecular genetic studies show that thousands of common and rare variants contribute to the genetic risk for psychosis. Epidemiological studies have identified many environmental factors associated with increased risk of psychosis. However, no single genetic or environmental factor is sufficient to cause psychosis on its own...
January 15, 2018: Psychological Medicine
https://www.readbyqxmd.com/read/29333672/controlled-pattern-imputation-for-sensitivity-analysis-of-longitudinal-binary-and-ordinal-outcomes-with-nonignorable-dropout
#2
Yongqiang Tang
The controlled imputation method refers to a class of pattern mixture models that have been commonly used as sensitivity analyses of longitudinal clinical trials with nonignorable dropout in recent years. These pattern mixture models assume that participants in the experimental arm after dropout have similar response profiles to the control participants or have worse outcomes than otherwise similar participants who remain on the experimental treatment. In spite of its popularity, the controlled imputation has not been formally developed for longitudinal binary and ordinal outcomes partially due to the lack of a natural multivariate distribution for such endpoints...
January 15, 2018: Statistics in Medicine
https://www.readbyqxmd.com/read/29332009/poststroke-psychosis-a-systematic-review
#3
REVIEW
Helle Stangeland, Vasiliki Orgeta, Vaughan Bell
A preregistered systematic review of poststroke psychosis examining clinical characteristics, prevalence, diagnostic procedures, lesion location, treatments, risk factors and outcome. Neuropsychiatric outcomes following stroke are common and severely impact quality of life. No previous reviews have focused on poststroke psychosis despite clear clinical need. CINAHL, MEDLINE and PsychINFO were searched for studies on poststroke psychosis published between 1975 and 2016. Reviewers independently selected studies for inclusion, extracted data and rated study quality...
January 13, 2018: Journal of Neurology, Neurosurgery, and Psychiatry
https://www.readbyqxmd.com/read/29331603/metabolic-risk-factors-in-schizophrenia-and-bipolar-disorder-the-effect-of-comedication-with-selective-serotonin-reuptake-inhibitors-and-antipsychotics
#4
K K Fjukstad, A Engum, S Lydersen, I Dieset, N Eiel Steen, O A Andreassen, O Spigset
BACKGROUND: The aim of this observational study was to investigate the relationship between metabolic factors and use of selective serotonin reuptake inhibitors (SSRIs) combined with olanzapine, quetiapine or risperidone. METHODS: Data from the Norwegian Thematically Organized Psychosis study, a cross-sectional study on 1301 patients with schizophrenia (n=868) or bipolar disorder (n=433), were analyzed. As exposure variables in the linear regression model were included the dose or serum concentration of SSRIs (n=280) and of olanzapine (n=398), quetiapine (n=234) or risperidone (n=128)...
April 17, 2017: European Psychiatry: the Journal of the Association of European Psychiatrists
https://www.readbyqxmd.com/read/29331192/-psychiatry-and-palliative-care-collaboration-for-the-benefit-of-the-patient
#5
REVIEW
Lionel Regard
As palliative care units continue to develop, the provision of end-of-life care for patients with a chronic mental illness needs to be addressed. Aside from the somatic comorbidities to which these patients are particularly exposed and in view of the specificity of psychiatric treatment, the forms of end-of-life support for a patient with schizophrenia are described here, based on the experience of a psychiatric unit in the Var region.
January 2018: Revue de L'infirmière
https://www.readbyqxmd.com/read/29329089/neural-circuit-dysfunction-in-mouse-models-of-neurodevelopmental-disorders
#6
REVIEW
Isabel Del Pino, Beatriz Rico, Oscar Marín
Neuropsychiatric disorders arise from the alteration of normal brain developmental trajectories disrupting the function of specific neuronal circuits. Recent advances in human genetics have greatly accelerated the identification of genes whose variation increases the susceptibility for neurodevelopmental disorders, most notably for autism spectrum disorder (ASD) and schizophrenia. In parallel, experimental studies in animal models-most typically in mice-are beginning to shed light on the role of these genes in the development and function of specific brain circuits...
January 9, 2018: Current Opinion in Neurobiology
https://www.readbyqxmd.com/read/29329042/assessment-of-the-efficacy-of-omega-3-fatty-acids-on-metabolic-and-inflammatory-parameters-in-patients-with-schizophrenia-taking-clozapine-and-sodium-valproate
#7
Fatemeh Behdani, Seyede Narjes Roudbaraki, Maryam Saberi-Karimian, Maryam Tayefi, Paria Hebrani, Amir Akhavanrezayat, Sadegh Vahabi Amlashi, Gordon A Ferns, Majid Ghayour-Mobarhan
Omega-3 fatty acid (FA) supplementation has been reported to improve several cardio-metabolic risk factors. We aimed to assess the efficacy of omega-3 fatty acids on metabolic and inflammatory indices in patients with schizophrenia who were taking clozapine and sodium valproate. All patients were on a stable dose of 300-400mg of clozapine for 3 months. Subjects were randomized to treatment with either omega-3 fatty acid (4gr/day) or a placebo for 8 weeks. Height, weight, abdominal circumference, serum lipid profile, fasting blood glucose (FBG), and serum high sensitivity-C-reactive protein (hs-CRP) were determined at baseline and after 8 weeks of treatment...
December 12, 2017: Psychiatry Research
https://www.readbyqxmd.com/read/29328779/transforming-the-treatment-of-schizophrenia-in-the-united-states-the-raise-initiative
#8
Lisa B Dixon, Howard Goldman, Vinod H Srihari, John M Kane
The schizophrenia spectrum disorders are neurodevelopmental illnesses with a lifetime prevalence near 1%, producing extensive functional impairment and low expectations for recovery. Until recently, treatment in the United States has largely attempted to stabilize individuals with chronic schizophrenia. The identification and promotion of evidence-based practices for schizophrenia via the Patient Outcomes Research Team, combined with international studies supporting the value of early intervention, provided the foundation for the Recovery After an Initial Schizophrenia Episode (RAISE) project...
January 12, 2018: Annual Review of Clinical Psychology
https://www.readbyqxmd.com/read/29326171/abdominal-vagal-afferents-modulate-the-brain-transcriptome-and-behaviors-relevant-to-schizophrenia
#9
Melanie Klarer, Jean-Philippe Krieger, Juliet Richetto, Ulrike Weber-Stadlbauer, Lydia Günther, Christine Winter, Myrtha Arnold, Wolfgang Langhans, Urs Meyer
Reduced activity of vagal efferents has long been implicated in schizophrenia and appears to be responsible for diminished parasympathetic activity and associated peripheral symptoms such as low heart rate variability and cardiovascular complications in affected individuals. In contrast, only little attention has been paid to the possibility that impaired afferent vagal signaling may be relevant for the disorder's pathophysiology as well. The present study explored this hypothesis using a model of subdiaphragmatic vagal deafferentation (SDA) in male rats...
January 11, 2018: Journal of Neuroscience: the Official Journal of the Society for Neuroscience
https://www.readbyqxmd.com/read/29325180/sertindole-eeg-analysis-tolerability-and-clinical-efficacy
#10
Adam Kroc, Marta Dębicka, Aleksandra Wierzbicka, Lidia Wołkow, Wojciech Jernajczyk, Adam Wichniak
INTRODUCTION: One of the common side effects of antipsychotic drugs is excessive sedation. The treatment with antipsychotics often manifests as an increase in slow wave activity in electroencephalography (EEG). The aim of this study was to analyze EEG recordings of patients treated with a non-sedative antipsychotic drug sertindole with regard to its adverse effects and clinical efficacy. PATIENTS AND METHODS: EEG recordings of 45 patients (27 females, mean age 30...
January 11, 2018: Pharmacopsychiatry
https://www.readbyqxmd.com/read/29324666/mapping-the-schizophrenia-genes-by-neuroimaging-the-opportunities-and-the-challenges
#11
REVIEW
Ayla Arslan
Schizophrenia (SZ) is a heritable brain disease originating from a complex interaction of genetic and environmental factors. The genes underpinning the neurobiology of SZ are largely unknown but recent data suggest strong evidence for genetic variations, such as single nucleotide polymorphisms, making the brain vulnerable to the risk of SZ. Structural and functional brain mapping of these genetic variations are essential for the development of agents and tools for better diagnosis, treatment and prevention of SZ...
January 11, 2018: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29321530/the-effect-of-raloxifene-augmentation-in-men-and-women-with-a-schizophrenia-spectrum-disorder-a-systematic-review-and-meta-analysis
#12
REVIEW
Janna de Boer, Merel Prikken, Wan U Lei, Marieke Begemann, Iris Sommer
Recognizing the robust sex differences in schizophrenia prevalence, the selective estrogen receptor modulator (SERM) raloxifene is a likely candidate for augmentation therapy in this disorder. Therefore, a systematic search was performed using PubMed (Medline), Embase, PsychInfo, and Cochrane Database of Systematic Reviews. Randomized controlled trials investigating the effect of raloxifene in schizophrenia spectrum disorders were included in the quantitative analyses. Outcome measures were psychotic symptom severity, depression, and cognition...
January 10, 2018: NPJ Schizophrenia
https://www.readbyqxmd.com/read/29320380/reducing-the-risk-of-type-2-diabetes-in-nonselected-outpatients-with-schizophrenia-a-30-month-program
#13
Peter Hjorth, Caroline H Espensen, Nikolaj J Madsen, Anne G Viuff, Povl Munk-Jørgensen
BACKGROUND: Type 2 diabetes is 2- to 3-fold more common in patients with schizophrenia than in the general population. A lifestyle with a focus on diet, exercise, and medication is required to prevent complications from type 2 diabetes, but patients with schizophrenia frequently have trouble maintaining such a lifestyle because of factors related to their illness, such as cognitive disturbances, negative and positive symptoms, and side effects of psychotropic medications. OBJECTIVE: To measure and reduce risk factors for type 2 diabetes in patients with schizophrenia and examine characteristics associated with positive outcomes...
January 2018: Journal of Psychiatric Practice
https://www.readbyqxmd.com/read/29318783/tak-063-a-novel-pde10a-inhibitor-with-balanced-activation-of-direct-and-indirect-pathways-provides-a-unique-opportunity-for-the-treatment-of-schizophrenia
#14
REVIEW
Kazunori Suzuki, Haruhide Kimura
The basal ganglia regulates motor, cognitive, and emotional behaviors. Dysfunction of dopamine system in this area is implicated in the pathophysiology of schizophrenia characterized by positive symptoms, negative symptoms, and cognitive deficits. Medium spiny neurons (MSNs) are principal output neurons of striatum in the basal ganglia. Similar to current antipsychotics with dopamine D2 receptor antagonism or partial agonism, phosphodiesterase 10A (PDE10A) inhibitors activate indirect pathway MSNs, leading to the expectation of therapeutic potential for the treatment of psychosis...
January 9, 2018: CNS Neuroscience & Therapeutics
https://www.readbyqxmd.com/read/29318771/safety-of-service-users-with-severe-mental-illness-receiving-inpatient-care-on-medical-and-surgical-wards-a-systematic-review
#15
REVIEW
Ella Reeves, Catherine Henshall, Marie Hutchinson, Debra Jackson
This review aimed to synthesize the evidence on the likelihood of harm and mortality on medical and surgical inpatient wards for people with severe mental illness (SMI). From 937 results identified through database searching, and a further 10 papers identified through citation searching and hand searching, 11 papers met the criteria for inclusion in the final review. This review did not find strong evidence for higher in-hospital mortality in people with SMI. There was evidence that adverse events are higher in people with SMI...
February 2018: International Journal of Mental Health Nursing
https://www.readbyqxmd.com/read/29317601/common-basis-for-orofacial-clefting-and-cortical-interneuronopathy
#16
Lydia J Ansen-Wilson, Joshua L Everson, Dustin M Fink, Henry W Kietzman, Ruth Sullivan, Robert J Lipinski
Orofacial clefts (OFCs) of the lip and/or palate are among the most common human birth defects. Current treatment strategies focus on functional and cosmetic repair but even when this care is available, individuals born with OFCs are at high risk for persistent neurobehavioral problems. In addition to learning disabilities and reduced academic achievement, recent evidence associates OFCs with elevated risk for a constellation of psychiatric outcomes including anxiety disorders, autism spectrum disorder, and schizophrenia...
January 10, 2018: Translational Psychiatry
https://www.readbyqxmd.com/read/29317600/altered-avalanche-dynamics-in-a-developmental-nmdar-hypofunction-model-of-cognitive-impairment
#17
Saurav Seshadri, Andreas Klaus, Daniel E Winkowski, Patrick O Kanold, Dietmar Plenz
Disturbed activity patterns in cortical networks contribute to the pathophysiology of schizophrenia (SZ). Several lines of evidence implicate NMDA receptor hypofunction in SZ, and blocking NMDA receptor signaling during early neurodevelopment produces cognitive deficits in rodent models that resemble those seen in schizophrenic patients. However, the altered network dynamics underlying these cognitive impairments largely remain to be characterized, especially at the cellular level. Here, we use in vivo two-photon calcium imaging to describe pathological dynamics, occurring in parallel with cognitive dysfunction, in a developmental NMDA receptor hypofunction model...
January 10, 2018: Translational Psychiatry
https://www.readbyqxmd.com/read/29317210/quality-indicators-in-the-treatment-of-patients-with-depression-bipolar-disorder-or-schizophrenia-consensus-study
#18
Miquel Bernardo, Consuelo de Dios, Víctor Pérez, Emilio Ignacio, Manuel Serrano, Eduard Vieta, José Joaquín Mira, Mercedes Guilabert, Miquel Roca
OBJECTIVE: To define a set of indicators for mental health care, monitoring quality assurance in schizophrenia, depression and bipolar disorders in Spain. MATERIAL AND METHOD: Qualitative research. Consensus-based study involving 6 psychiatrists on the steering committee and a panel of 43 psychiatrists working in several health services in Spain. An initial proposal of 44 indicators for depression, 42 for schizophrenia and 58 for bipolar disorder was elaborated after reviewing the literature...
January 6, 2018: Revista de Psiquiatrí́a y Salud Mental
https://www.readbyqxmd.com/read/29315577/bidirectional-variation-in-glutamate-efflux-in-the-medial-prefrontal-cortex-induced-by-selective-positive-and-negative-allosteric-mglur5-modulators
#19
Sarah N Isherwood, Trevor W Robbins, Jeffrey W Dalley, Anton Pekcec
Dysregulation of prefrontal cortical glutamatergic signalling via NMDA receptor hypofunction has been implicated in cognitive dysfunction and impaired inhibitory control in such neuropsychiatric disorders as schizophrenia, attention deficit hyperactivity disorder and drug addiction. Although NMDA receptors functionally interact with metabotropic glutamate receptor 5 (mGluR5), the consequence of this interaction for glutamate release in the prefrontal cortex (PFC) is unknown. We therefore investigated the effects of positive and negative allosteric mGluR5 modulation on changes in extracellular glutamate efflux in the medial PFC (mPFC) induced by systemic administration of the non-competitive NMDA receptor antagonist dizocilpine (or MK801) in rats...
January 6, 2018: Journal of Neurochemistry
https://www.readbyqxmd.com/read/29311510/discovery-and-development-of-muscarinic-acetylcholine-m4-activators-as-promising-therapeutic-agents-for-cns-diseases
#20
Kentaro Takai, Takeshi Enomoto
Among the muscarinic acetylcholine receptor (mAChR) subtypes, the M4 receptor has been investigated as a promising drug target for the treatment of schizophrenia. These investigations have been based on findings from M4-deficient mice studies as well as on the results of a clinical trial that used xanomeline, an M1/M4 mAChRs-preferring agonist. Both orthosteric agonists and positive allosteric modulators of M4 mAChR have been reported as promising ligands that not only have antipsychotic effects, but can also improve cognitive impairment and motor dysfunction...
2018: Chemical & Pharmaceutical Bulletin
keyword
keyword
50210
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"